Price
$215.77-3.54%Social Signal Score
Analyst Ratings
27 analystsRevenue
$259.69MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Herriot Tabuteau
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,346
- Beta
- 0.60
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.14
Financials
Revenue
$259.69M+2844.3%Net Income
$-12.88MEBITDA
$-11.07MFree Cash Flow
$-9.67MEPS (diluted)
$-0.25Shares Outstanding (diluted)
52.45M+173.8%Operating Expenses
$253.73MCash & Debt
$313.86MRevenue by Segment (annual)
$633.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $638.50M | $-183.17M | $-3.68 |
| 2024 | $385.69M | $-287.22M | $-5.99 |
| 2023 | $270.60M | $-239.24M | $-5.27 |
| 2022 | $50.04M | $-187.13M | $-4.60 |
| 2021 | $0.00 | $-130.40M | $-3.47 |
| 2020 | $0.00 | $-102.90M | $-2.83 |
| 2019 | $0.00 | $-68.35M | $-2.05 |
| 2018 | $0.00 | $-30.97M | $-1.15 |
| 2017 | $0.00 | $-28.94M | $-1.27 |
| 2016 | $0.00 | $-27.20M | $-1.42 |
| 2015 | $0.00 | $-12.21M | $-0.88 |
| 2014 | $0.00 | $-6.00M | $-0.47 |
| 2013 | $0.00 | $-2.17M | $-0.28 |
Valuation
AXSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (53)
- Newsglobenewswire.com·3d ago·Neutral
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December:
View source ↗ - Newsmarketbeat.com·6d ago·Negative
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer's Agitation Launch Axsome Therapeutics NASDAQ: AXSM executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug's launch for Alzheimer's disease agitation.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - News (RSS)fool·8d ago·Negative
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027? Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge Axsome Therapeutics NASDAQ: AXSM reported $260 million in third-quarter revenue, driven by growth in its AUVELITY treatment for major depressive disorder and Alzheimer's disease agitation, executives said at the Guggenheim Healthcare Innovation Conference.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Axsome Therapeutics, Inc. ( AXSM ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 11:30 AM EST Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All righ…
View source ↗ - Newsfool.com·17d ago·Positive
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027? Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade) Axsome Therapeutics (AXSM) is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA approval. AUVELITY's ADA launch is progressing slower than hoped, with incremental growth driven more by under-65 depression scripts than ADA scripts. Q3 results showed a technical beat, but underlying sales were padded by one-time items and improved gross-to-net, not sustainable volume growth.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
View source ↗ - News (Marketaux)seekingalpha.com·20d ago·Neutral
Axsome Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-11-02 Axsome Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-11-02
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's disease agitation.
View source ↗ - Newszacks.com·20d ago·Neutral
Axsome (AXSM) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·20d ago·Negative
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.
View source ↗ - Newsglobenewswire.com·20d ago·Negative
…king cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update. “Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annua…
View source ↗ - Newszacks.com·27d ago·Neutral
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsfool.com·30d ago·Positive
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks) Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.
View source ↗ - Newszacks.com·32d ago·Neutral
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
View source ↗ - News (RSS)fool·41d ago·Neutral
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? Auvelity's Alzheimer's expansion could transform Axsome by 2030.
View source ↗ - Newsfool.com·41d ago·Negative
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? Axsome sees at least $8 billion in potential peak Auvelity sales. Additional drugs and pipeline candidates could fuel long-term growth.
View source ↗ - News (RSS)fool·45d ago·Positive
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. E…
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
…ns, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheim…
View source ↗ - Newsmarketbeat.com·64d ago·Neutral
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.
View source ↗ - Newsmarketbeat.com·64d ago·Neutral
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.
View source ↗ - News (RSS)fool·65d ago·Neutral
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
View source ↗ - Newsfool.com·65d ago·Positive
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.
View source ↗ - News (RSS)fool·65d ago·Negative
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
View source ↗ - Newsfool.com·65d ago·Negative
Is Axsome Therapeutics a Buy on the Dip? Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player's late-stage pipeline could translate into additional products over the next few years.
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
…Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, bei…
View source ↗ - Newsseekingalpha.com·67d ago·Neutral
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·72d ago·Positive
Axsome rises on Auvelity prescription data
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·73d ago·Negative
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·74d ago·Neutral
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m.
View source ↗ - News (Marketaux)gurufocus.com·83d ago·Positive
Axsome Therapeutics (AXSM) Gains Buy Rating Amid Smoking Cessation Trial, But Valuation Remains Elevated Wainwright reaffirmed its Buy rating on [+276 characters]
View source ↗ - News (RSS)investing·83d ago·Neutral
Axsome doses first patient in phase 3 smoking cessation trial
View source ↗ - News (RSS)yahoo·85d ago·Positive
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
View source ↗ - News (Marketaux)finance.yahoo.com·91d ago·Positive
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run Axsome Therapeutics (<[+293 characters]
View source ↗ - News (RSS)fool·91d ago·Neutral
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run The company has also crushed broader equities over the past five years.
View source ↗ - Newsfool.com·91d ago·Neutral
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company's deep pipeline may help it launch newer products and post consistent revenue growth for a while.
View source ↗ - Newszacks.com·103d ago·Negative
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt
View source ↗ - News (Marketaux)seekingalpha.com·103d ago·Neutral
Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11 Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-08-11
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·104d ago·Neutral
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·104d ago·Negative
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
View source ↗ - Newsmarketbeat.com·104d ago·Positive
Axsome Therapeutics Q2 Earnings Call Highlights Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build.
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $-0.05 per share
Typical surprise -1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$-0.25 vs $-0.63beat
- Mon, Aug 10$-0.99 vs $-0.89miss
- Mon, May 4$-1.26 vs $-0.85miss
- Mon, Feb 23$-0.71 vs $-0.70miss
- Mon, Nov 3$-0.94 vs $-0.82miss
- Mon, Aug 4$-0.92 vs $-1.00beat
Estimates and results for AXSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AXSM officers and directors.
- Bought
- —
- Sold
- $111.5m
0 trades
29 trades
- Jacobson Mark L.sold
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·4,660 @ $213.95·$997k·Aug 6, 2026·filing
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·45,004 @ $212.01·$9.5m·Aug 5, 2026·filing
- Tabuteau Herriotsolddirector, 10 percent owner, officer: Chief Executive Officer·49,666 @ $240.25·$11.9m·Jul 1, 2026·filing
- Jeffs Rogersold
- Jeffs Rogersold
- Mahony Susansold
- Coleman Marksold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AXSM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
